{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:06:41Z","timestamp":1793394401832,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04286"],"award-info":[{"award-number":["17H04286"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1245\/s10434-020-09007-2","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T15:06:05Z","timestamp":1597676765000},"page":"5057-5064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer"],"prefix":"10.1245","volume":"27","author":[{"given":"Hideyuki","family":"Ohzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Miyato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunaru","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanaga","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Kawarai","family":"Lefor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-7130","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"issue":"3","key":"9007_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol."},{"issue":"1","key":"9007_CR2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12032-012-0451-1","volume":"30","author":"AH Anter","year":"2013","unstructured":"Anter AH, Abdel-Latif RM. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Med. Oncol. 2013;30(1):451.","journal-title":"Med. Oncol."},{"issue":"1","key":"9007_CR3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1186\/s12885-019-6294-9","volume":"19","author":"X Guo","year":"2019","unstructured":"Guo X, Zhao F, Ma X, et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC cancer. 2019;19(1):1125.","journal-title":"BMC cancer."},{"issue":"3","key":"9007_CR4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/02841860600791483","volume":"46","author":"SY Oh","year":"2007","unstructured":"Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol. 2007;46(3):336\u201341.","journal-title":"Acta Oncol."},{"key":"9007_CR5","doi-asserted-by":"crossref","unstructured":"Shirao K, Boku N, Yamada Y, et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Japanese J Clin Oncol. 2013;43(10):972\u201380.","DOI":"10.1093\/jjco\/hyt114"},{"issue":"1","key":"9007_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10120-012-0143-8","volume":"16","author":"K Shitara","year":"2013","unstructured":"Shitara K, Mizota A, Matsuo K, et al. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16(1):48\u201355.","journal-title":"Gastric Cancer."},{"issue":"3","key":"9007_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4251\/wjgo.v9.i3.121","volume":"9","author":"HL Tan","year":"2017","unstructured":"Tan HL, Chia CS, Tan GH, et al. Gastric peritoneal carcinomatosis - a retrospective review. World J Gastrointest Oncol. 2017;9(3):121\u20138.","journal-title":"World J Gastrointest Oncol."},{"issue":"9","key":"9007_CR8","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"131","key":"9007_CR9","first-page":"703","volume":"61","author":"H Muller","year":"2014","unstructured":"Muller H, Hotopp T, Tofeili A, Wutke K. Systemic chemotherapy using FLOT - regimen combined with cytoreductive surgery plus HIPEC for treatment of peritoneal metastasized gastric cancer. Hepatogastroenterology. 2014;61(131):703\u20136.","journal-title":"Hepatogastroenterology."},{"issue":"6","key":"9007_CR10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"9007_CR11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1984.2.11.1277","volume":"2","author":"CE Pfeifle","year":"1984","unstructured":"Pfeifle CE, Howell SB, Markman M, Lucas WE. Totally implantable system for peritoneal access. J Clin Oncol. 1984;2(11):1277\u201380.","journal-title":"J Clin Oncol."},{"issue":"4","key":"9007_CR12","first-page":"1150","volume":"14","author":"K Kimura","year":"1987","unstructured":"Kimura K, Koide A, Suga S, et al. [Clinical experience of a subcutaneously implantable drug delivery catheter (PORT-A-CATH)]. Gan to kagaku ryoho. Cancer Chemother. 1987;14(4):115\u2013-5.","journal-title":"Gan to kagaku ryoho. Cancer Chemother."},{"issue":"5","key":"9007_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277\u201383.","journal-title":"Lancet Oncol."},{"issue":"11","key":"9007_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4251\/wjgo.v7.i11.285","volume":"7","author":"H Yamaguchi","year":"2015","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. World J Gastrointest Oncol. 2015;7(11):285\u201391.","journal-title":"World J Gastrointest Oncol."},{"issue":"19","key":"9007_CR15","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol."},{"issue":"2","key":"9007_CR16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ags3.12060","volume":"2","author":"J Kitayama","year":"2018","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2(2):116\u201323.","journal-title":"Ann Gastroenterol Surg."},{"issue":"3","key":"9007_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2012.08.008","volume":"65","author":"S El Andaloussi","year":"2013","unstructured":"El Andaloussi S, Lakhal S, Mager I, Wood MJ. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev. 2013;65(3):391\u20137.","journal-title":"Adv Drug Deliv Rev."},{"issue":"4","key":"9007_CR18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213\u201328.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"10","key":"9007_CR19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. Oct 2009;10(10):704\u201314.","journal-title":"Nat Rev Genet."},{"issue":"3","key":"9007_CR20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10147-017-1104-3","volume":"22","author":"J Matsuzaki","year":"2017","unstructured":"Matsuzaki J, Ochiya T. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int J Clin Oncol. 2017;22(3):413\u201320.","journal-title":"Int J Clin Oncol."},{"issue":"2","key":"9007_CR21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/cgt.2016.77","volume":"24","author":"R Nedaeinia","year":"2017","unstructured":"Nedaeinia R, Manian M, Jazayeri MH, et al. Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer. Cancer Gene Ther. 2017;24(2):48\u201356.","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"9007_CR22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816\u201326.","journal-title":"Nat Cell Biol."},{"issue":"4","key":"9007_CR23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bjc.2013.795","volume":"110","author":"I Shapira","year":"2014","unstructured":"Shapira I, Oswald M, Lovecchio J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 2014;110(4):976\u201383.","journal-title":"Br J Cancer."},{"issue":"13","key":"9007_CR24","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/onc.2016.353","volume":"36","author":"KE Richards","year":"2017","unstructured":"Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2017;36(13):1770\u20138.","journal-title":"Oncogene."},{"issue":"1","key":"9007_CR25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ags3.12296","volume":"4","author":"H Ohzawa","year":"2019","unstructured":"Ohzawa H, Kumagai Y, Yamaguchi H, et al. Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer. Ann Gastrointest Surg. 2019;4(1):84\u201393.","journal-title":"Ann Gastrointest Surg."},{"issue":"4","key":"9007_CR26","first-page":"1081","volume":"43","author":"H Ohzawa","year":"2020","unstructured":"Ohzawa H, Saito A, Kumagai Y, et al. Reduced expression of exosomal miR29s in peritoneal fluid is a useful predictor of peritoneal recurrence after curative resection of gastric cancer with serosal involvement. Oncol Rep. 2020;43(4):1081\u20138.","journal-title":"Oncol Rep."},{"issue":"16","key":"9007_CR27","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","volume":"107","author":"W Blum","year":"2010","unstructured":"Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16):7473\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"9007_CR28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3892\/or.2014.3036","volume":"31","author":"H Jiang","year":"2014","unstructured":"Jiang H, Zhang G, Wu JH, Jiang CP. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014;31(4):1509\u201316.","journal-title":"Oncol Rep."},{"issue":"9","key":"9007_CR29","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/abbs\/gmx078","volume":"49","author":"T Liu","year":"2017","unstructured":"Liu T, Chen G, Sun D, et al. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai). 2017;49(9):808\u201316.","journal-title":"Acta Biochim Biophys Sin (Shanghai)."},{"issue":"10","key":"9007_CR30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/13894501113149990185","volume":"14","author":"H Seca","year":"2013","unstructured":"Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM, Vasconcelos MH. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets. 2013;14(10):1135\u201343.","journal-title":"Curr Drug Targets."},{"issue":"19","key":"9007_CR31","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1158\/0008-5472.CAN-16-1092","volume":"76","author":"SA Bliss","year":"2016","unstructured":"Bliss SA, Sinha G, Sandiford OA, et al. Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 2016;76(19):5832-44.","journal-title":"Cancer Res."},{"issue":"6","key":"9007_CR32","first-page":"2512","volume":"8","author":"R Li","year":"2016","unstructured":"Li R, Wu S, Chen X, Xu H, Teng P, Li W. miR-223\/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer. Am J Transl Res. 2016;8(6):2512\u201324.","journal-title":"Am J Transl Res."},{"issue":"18","key":"9007_CR33","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354\u20138.","journal-title":"Cancer."},{"key":"9007_CR34","doi-asserted-by":"crossref","unstructured":"Fujiwara Y, Ishigami H, Miwa H, et al. Phase II study of intraperitoneal paclitaxel plus S-1\/oxaliplatin for gastric cancer with peritoneal metastasis: SOX\u2009+\u2009IP PTX trial. J Clin Oncol. 2016;34(15(suppl)):Abst. 4040.","DOI":"10.1200\/JCO.2016.34.15_suppl.4040"},{"issue":"4","key":"9007_CR35","doi-asserted-by":"crossref","first-page":"e95240","DOI":"10.1371\/journal.pone.0095240","volume":"9","author":"WX Chen","year":"2014","unstructured":"Chen WX, Liu XM, Lv MM, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PloS One. 2014;9(4):e95240.","journal-title":"PloS One."},{"key":"9007_CR36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cellsig.2017.07.005","volume":"38","author":"GR Raji","year":"2017","unstructured":"Raji GR, Sruthi TV, Edatt L, Haritha K, Sharath Shankar S, Sameer Kumar VB. Horizontal transfer of miR-106a\/b from cisplatin resistant hepatocarcinoma cells can alter the sensitivity of cervical cancer cells to cisplatin. Cell Signal. 2017;38:146\u201358.","journal-title":"Cell Signal."},{"issue":"12","key":"9007_CR37","doi-asserted-by":"crossref","first-page":"R663","DOI":"10.1530\/ERC-18-0019","volume":"25","author":"M Alharbi","year":"2018","unstructured":"Alharbi M, Zuniga F, Elfeky O, et al. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocr Relat Cancer. 2018;25(12):R663\u201385.","journal-title":"Endocr Relat Cancer."},{"key":"9007_CR38","doi-asserted-by":"crossref","unstructured":"Morini M, Cangelosi D, Segalerba D, et al. Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients: a proof of concept SIOPEN Study. Cancers (Basel). 2019;11(10).","DOI":"10.3390\/cancers11101476"},{"issue":"4","key":"9007_CR39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/CBM-161732","volume":"18","author":"M Qi","year":"2017","unstructured":"Qi M, Liu D, Zhang S. MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer. Cancer Biomark. 2017;18(4):451\u20138.","journal-title":"Cancer Biomark."},{"issue":"3","key":"9007_CR40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.28399","volume":"134","author":"PN Yu","year":"2014","unstructured":"Yu PN, Yan MD, Lai HC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014;134(3):542\u201351.","journal-title":"Int J Cancer."},{"key":"9007_CR41","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.12659\/MSM.911972","volume":"24","author":"W Xu","year":"2018","unstructured":"Xu W, Li Z, Zhu X, Xu R, Xu Y. miR-29 Family inhibits resistance to methotrexate and promotes cell apoptosis by targeting COL3A1 and MCL1 in osteosarcoma. Med Sci Monit. 2018;24:8812\u201321.","journal-title":"Med Sci Monit."},{"key":"9007_CR42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tiv.2017.02.005","volume":"40","author":"S Kollinerova","year":"2017","unstructured":"Kollinerova S, Dostal Z, Modriansky M. MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1. Toxicol In Vitro. 2017;40:289\u201396.","journal-title":"Toxicol In Vitro."},{"issue":"35","key":"9007_CR43","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1073\/pnas.0805038105","volume":"105","author":"E van Rooij","year":"2008","unstructured":"van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027\u201332.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"9007_CR44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1165\/rcmb.2010-0323OC","volume":"45","author":"L Cushing","year":"2011","unstructured":"Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(2):287\u201394.","journal-title":"Am J Respir Cell Mol Biol."},{"issue":"26","key":"9007_CR45","doi-asserted-by":"crossref","first-page":"42262","DOI":"10.18632\/oncotarget.15040","volume":"8","author":"M Wei","year":"2017","unstructured":"Wei M, Yang T, Chen X, et al. Malignant ascites-derived exosomes promote proliferation and induce carcinoma-associated fibroblasts transition in peritoneal mesothelial cells. Oncotarget. 2017;8(26):42262\u201371.","journal-title":"Oncotarget."},{"issue":"2","key":"9007_CR46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2017.0182","volume":"15","author":"Y Tian","year":"2018","unstructured":"Tian Y, Sun C, Zhang L, Pan Y. Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy. Cancer Biol Med. 2018;15(2):157\u201364.","journal-title":"Cancer Biol Med."},{"key":"9007_CR47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-015-0220-7","volume":"8","author":"G Lou","year":"2015","unstructured":"Lou G, Song X, Yang F, et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8:122.","journal-title":"J Hematol Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09007-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T23:10:54Z","timestamp":1629155454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09007-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9007"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09007-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interests on this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}